← feed

Is NCT03176264 results overdue?

Yes — results are overdue. Primary completion was 2018-01-30; the FDAAA-801 reporting deadline (2019-01-30) passed 2699 days ago and no results are posted on ClinicalTrials.gov.

PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

NCT IDNCT03176264 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusTERMINATED
Primary completion2018-01-30 (ACTUAL)
Reporting deadline2019-01-30 (completion + 365d)
Days overdue2699
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 457152cc57ec4707… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03176264. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →